Wednesday, November 13, 2013, 11:00 a.m. - 11:55 a.m., Room 403
China has committed to making private healthcare a larger part of the overall ecosystem, aiming for 20% of beds and 20% of spending to be conducted through private institutions by 2020. In order achieve this ambitious goal, the government has laid out multiple policy initiatives aiming to relax historical constraints that have previously limited growth. These changes have unleashed a wave of growth in private healthcare that is only just beginning. In this panel, we will explore the opportunities and challenges for private insurers, providers, pharmaceutical companies and device manufacturers looking to capitalize on the rapidly growth in private healthcare.
- Maykin Ho, PhD, Advisory Director, Goldman Sachs
- Helen Chen, Director & Partner, L.E.K Consulting
- Peter Liu, MD, Director and Founder, Delta Health
- Lawrence Wang, MD, Managing Director, Primavera Capital Group
Helen Chen is a Director and Partner at L.E.K. Consulting and is the Co-Head of the China practice in Shanghai. She is also the head of L.E.K.’s China Biopharmaceuticals & Life Sciences practice and has extensive case work and industry experience covering the full biopharmaceutical value chain, ranging from early research services and portfolio evaluations to post-market product positioning and sales force effectiveness.
Helen has more than 23 years of consulting and industry experience in the U.S. and Asia markets and has resided in China since 2000. She helps companies expand their presence in China and leverages China’s resources to improve their global businesses. She is on the Editorial Board of PharmAsia and is a frequent speaker and author on the opportunities and issues in China’s Healthcare and Life Sciences sectors. Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China. She was an associate director of finance at Genentech and a sales planner at Abbott Laboratories.
Helen has an honors degree in Applied Mathematics from Harvard University and attended the Kellogg Graduate School of Management at Northwestern University.
Maykin Ho, PhD
Dr. Ho is an advisory director to the firm. Previously, she was a biotechnology analyst and co-head of US Healthcare for Global Investment Research. She joined Goldman Sachs in 1992 and was named managing director in 1998 and partner in 2002.
Dr. Ho has been ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for over 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times. Prior to joining the firm, she held senior management positions in research, marketing and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company.
Dr. Ho serves on the board of The Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University and the Investment Committee of the Society for Neuroscience. She has also served on the Biological Chemistry Advisory Council at Harvard Medical School. Dr. Ho was a postdoctoral fellow at Harvard Medical School. She earned a PhD in Microbiology and Immunology from the State University of New York, Downstate Medical Center.
Peter Liu, MD, Director and Founder
*Biography coming soon.
Lawrence Wang, MD
Lawrence is currently managing director and head of healthcare for Primavera Capital. Previous to joining Primavera, he was Head of Asia Healthcare for Macquarie Capital and prior to Macquarie, was an Executive Director in Goldman Sachs with roles in GS Direct Asia in Hong Kong and healthcare investment banking both in Hong Kong and New York.
Lawrence holds a Bachelor of Arts in Biology and Economics and a Doctor of Medicine from Boston University and an MBA from MIT Sloan School of Management.